WJPMR, 2026, 12(6), 01-09

Review Article

Impact Factor: 7.533

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

ISSN (O): 2455-3301
ISSN (P): 3051-2557
Coden USA: WJPMBB

METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF NIMESULIDE & DICLOFENAC IN PHARMACEUTICAL FORMULATIONS WITH THE HELP OF UV-VISIBLE SPECTROSCOPY: A REVIEW

Gaurav Bhausaheb Gayakwad*

India.

***Corresponding Author: Gaurav Bhausaheb Gayakwad**

PG Scholar, Department of Kayachikitsa, PMT Ayurveda College and Shri Eknath Ayurved Rugnalaya, Shevgaon, Ahilyanagar, Maharashtra, India.

DOI: https://doi.org/10.5281/zenodo.20444149

How to cite this Article: Gaurav Bhausaheb Gayakwad* (2026). Method Development And Validation For Estimation Of Nimesulide & Diclofenac In Pharmaceutical Formulations With The Help Of Uv-Visible Spectroscopy: A Review. World Journal of Pharmaceutical and Medical Research, 12(6), 01–09.

Article Received on 29/04/2026 **Article Revised on 19/05/2026** **Article Published on 01/06/2026**

ABSTRACT

The growing demand for safe, effective, and high-quality pharmaceutical formulations necessitates the development of reliable analytical methods for drug estimation and quality control. Nimesulide and Diclofenac are widely used non-steroidal anti-inflammatory drugs (NSAIDs) frequently formulated in combination to achieve enhanced therapeutic efficacy through synergistic action. The simultaneous estimation of these drugs in pharmaceutical dosage forms is therefore essential for ensuring product quality, safety, and regulatory compliance. This review focuses on UV–Visible spectrophotometric methods developed for the simultaneous estimation of Nimesulide and Diclofenac. UV spectroscopy is widely preferred in pharmaceutical analysis due to its simplicity, rapidity, cost-effectiveness, and minimal requirement for complex instrumentation. The technique is based on the absorption of ultraviolet radiation by drug molecules, following Beer–Lambert's law, which establishes a direct relationship between absorbance and concentration within a defined linear range. Typically, Nimesulide exhibits maximum absorbance (λmax) around 390–395 nm, while Diclofenac shows λmax near 275–280 nm, enabling their simultaneous quantification. Various analytical approaches have been employed for simultaneous estimation, including the simultaneous equation method, absorbance ratio method (Q-analysis), and derivative spectrophotometry. The simultaneous equation method utilizes absorbance measurements at two selected wavelengths to calculate the concentration of each drug. The Q-analysis method involves the use of an isoabsorptive point along with the λmax of one component, offering improved accuracy and simplicity. Derivative spectroscopy enhances spectral resolution and selectivity, particularly in cases of overlapping spectra, thereby minimizing interference. Method validation is performed in accordance with International Council for Harmonization (ICH Q2(R1)) guidelines to ensure reliability and reproducibility. Key validation parameters include linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ), robustness, and specificity. Reported methods demonstrate excellent linearity within concentration ranges of 5–30 µg/mL, with correlation coefficients exceeding 0.999. Accuracy is confirmed through recovery studies (98–102%), while precision is indicated by relative standard deviation values below 2%. LOD and LOQ values confirm adequate sensitivity, and robustness studies indicate minimal impact of small variations in analytical conditions. A review of the literature reveals that UV spectrophotometric methods provide consistent, accurate, and reproducible results for routine analysis of Nimesulide and Diclofenac in pharmaceutical formulations such as tablets and capsules. Although these methods are less sensitive than advanced chromatographic techniques, their simplicity, rapid analysis, and cost-effectiveness make them highly suitable for routine quality control applications.

KEYWORDS: Nimesulide and Diclofenac in pharmaceutical formulations such as tablets and capsules.

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely utilized classes of therapeutic agents in modern medicine, primarily indicated for the management of pain, inflammation, and fever. Their mechanism of action is largely attributed to the inhibition of cyclooxygenase (COX) enzymes, which are responsible for the biosynthesis of prostaglandins—

key mediators involved in inflammatory responses and pain perception. Among the numerous NSAIDs available, Nimesulide and Diclofenac have gained considerable clinical importance due to their potent pharmacological activity and widespread therapeutic applications.

Nimesulide is a selective COX-2 inhibitor that exhibits pronounced anti-inflammatory, analgesic, and antipyretic properties with comparatively reduced gastrointestinal side effects relative to non-selective NSAIDs. It is chemically designated as N-(4-nitro-2-phenoxyphenyl) methanesulfonamide and is characterized by its rapid onset of action and favorable pharmacokinetic profile. Diclofenac, on the other hand, is a widely prescribed non-selective NSAID belonging to the phenylacetic acid class. It demonstrates strong inhibition of both COX-1 and COX-2 enzymes, making it highly effective in the treatment of conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute musculoskeletal pain. The combination of Nimesulide and Diclofenac in pharmaceutical dosage forms is often employed to achieve synergistic therapeutic effects, thereby enhancing efficacy while potentially reducing the required dose of individual drugs.

The increasing prevalence of combination drug formulations necessitates the development of robust, accurate, and reliable analytical methods for their simultaneous estimation. Analytical method development plays a critical role in ensuring the quality, safety, and efficacy of pharmaceutical products. Regulatory authorities such as the International Council for Harmonization (ICH) mandate the validation of analytical methods to demonstrate their suitability for intended applications. The validation process encompasses several parameters, including linearity, accuracy, precision, specificity, robustness, and sensitivity, all of which collectively ensure the reliability and reproducibility of the analytical results.

In the context of pharmaceutical analysis, a wide range of analytical techniques has been employed for the estimation of drug substances, including high-performance liquid chromatography (HPLC), gas chromatography (GC), liquid chromatography–mass spectrometry (LC-MS), and spectroscopic methods. While chromatographic techniques offer high sensitivity and specificity, they often require expensive instrumentation, extensive sample preparation, and longer analysis times. In contrast, UV–Visible spectrophotometry presents a simpler, faster, and more economical alternative, making it particularly suitable for routine quality control analysis in pharmaceutical industries and academic laboratories.

UV–Visible spectrophotometry is based on the principle of absorption of ultraviolet or visible radiation by molecules, resulting in electronic transitions between molecular orbitals. The quantitative analysis of drug substances using UV spectroscopy is governed by Beer–Lambert's law, which establishes a linear relationship between absorbance and concentration within a defined range. This relationship enables the determination of drug concentration in a sample by measuring its absorbance at a specific wavelength. The selection of appropriate analytical wavelengths (λmax) is a critical step in method development, as it directly influences the sensitivity and specificity of the analysis. Nimesulide typically exhibits a maximum absorbance around 390–395 nm due to its chromophoric nitro group, whereas Diclofenac shows maximum absorbance in the range of 275–280 nm, attributed to its aromatic structure.

One of the primary challenges in the simultaneous estimation of two or more drugs using UV spectroscopy is the overlap of their absorption spectra. This spectral interference can complicate the accurate quantification of individual components in a mixture. To address this challenge, several mathematical and instrumental approaches have been developed. The simultaneous equation method is widely used and involves measuring absorbance at two selected wavelengths corresponding to the λmax of each drug, followed by solving linear equations to determine their respective concentrations. Another approach, known as the absorbance ratio method or Q-analysis, utilizes an isoabsorptive point—a wavelength at which both drugs exhibit equal absorbance—along with the λmax of one of the components. This method simplifies calculations and improves accuracy in certain cases.

Derivative spectrophotometry represents a more advanced approach that enhances spectral resolution by converting normal absorption spectra into their derivatives. This technique is particularly useful in resolving overlapping spectra and eliminating background interference from excipients or degradation products. First-order derivative spectroscopy is commonly employed for the simultaneous estimation of Nimesulide and Diclofenac, as it allows for the selective measurement of each drug at zero-crossing points, thereby improving specificity and sensitivity.

Method development in UV spectrophotometry involves several critical steps, including the selection of suitable solvents, preparation of standard and working solutions, determination of λmax, and construction of calibration curves. The choice of solvent is particularly important, as it must provide adequate solubility for the drugs while minimizing interference in the UV region. Commonly used solvents include methanol, ethanol, and phosphate buffer systems. Calibration curves are constructed by plotting absorbance against concentration, and the linearity of the method is evaluated over a specified concentration range.

Method validation, as per ICH Q2(R1) guidelines, is an essential component of analytical method development. Linearity is assessed by evaluating the correlation coefficient (R^2), which should ideally be greater than 0.999. Accuracy is determined through recovery studies, where known amounts of the drug are added to the sample and analyzed to assess the percentage recovery. Precision is evaluated in terms of repeatability and intermediate precision, typically expressed as relative standard deviation (RSD). The limit of detection (LOD) and limit of quantification (LOQ) are calculated to determine the sensitivity of the method. Robustness studies involve making deliberate small variations in experimental conditions to assess the reliability of the method under different circumstances. Specificity ensures that the method can accurately measure the analyte in the presence of other components such as excipients and degradation products.

A comprehensive review of the literature indicates that numerous UV spectrophotometric methods have been developed for the simultaneous estimation of Nimesulide and Diclofenac in pharmaceutical dosage forms. These methods have demonstrated satisfactory validation parameters, indicating their suitability for routine analysis. Comparative studies suggest that while simpler methods such as simultaneous equation and Q-analysis are widely used due to their ease of implementation, derivative spectroscopy offers superior selectivity in cases of significant spectral overlap.

Despite the availability of advanced analytical techniques, UV–Visible spectrophotometry continues to be a preferred choice for routine quality control due to its inherent advantages, including low cost, minimal maintenance, rapid analysis, and ease of operation. However, it is important to acknowledge its limitations, such as lower sensitivity compared to chromatographic methods and potential interference from complex matrices. Nevertheless, with appropriate method development and validation strategies, these limitations can be effectively mitigated.

In recent years, there has been growing interest in enhancing the capabilities of UV spectrophotometric methods through the integration of chemometric techniques, such as multivariate calibration and artificial neural networks. These approaches enable the simultaneous analysis of multiple components in complex mixtures with improved accuracy and precision. Such advancements hold significant promise for the future of UV spectroscopy in pharmaceutical analysis.

In conclusion, the development and validation of UV–Visible spectrophotometric methods for the simultaneous estimation of Nimesulide and Diclofenac are of paramount importance in ensuring the quality and safety of pharmaceutical formulations. The present review aims to provide a comprehensive overview of the principles, methodologies, and validation strategies associated with these methods, along with a critical evaluation of reported studies. This work is expected to serve as a valuable reference for researchers, analysts, and quality control professionals involved in pharmaceutical analysis.

DRUG PROFILE

1. Nimesulide

General Information

Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) belonging to the sulfonanilide class, widely recognized for its selective inhibition of cyclooxygenase-2 (COX-2). It is primarily used for its analgesic, anti-inflammatory, and antipyretic effects. Unlike conventional NSAIDs, Nimesulide exhibits preferential COX-2 inhibition, which contributes to reduced gastrointestinal toxicity.

Chemical and Physicochemical Properties

- Chemical Name: N-(4-nitro-2-phenoxyphenyl) methanesulfonamide
- Molecular Formula: $C_{13}H_{12}N_2O_5S$
- Molecular Weight: 308.31 g/mol
- Structure: Contains nitro ($-NO_2$), sulfonamide ($-SO_2NH$), and ether (-O-) functional groups
- Solubility: Practically insoluble in water; freely soluble in organic solvents such as methanol and ethanol
- pKa: ~6.5
- Log P: ~3.1 (indicating moderate lipophilicity)

The presence of strong chromophoric groups such as the nitro group contributes significantly to its UV absorption characteristics.

Pharmacological Profile

Nimesulide exhibits its pharmacological activity primarily through selective inhibition of COX-2 enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation and pain. Additionally, it demonstrates.

- Inhibition of free radical generation.
- Reduction in histamine release.
- Suppression of tumor necrosis factor-alpha (TNF-α)

These additional mechanisms contribute to its enhanced anti-inflammatory activity compared to traditional NSAIDs.

Pharmacokinetics

Absorption: Rapidly absorbed after oral administration

- Bioavailability: ~100%
- Protein Binding: ~99%
- Metabolism: Extensively metabolized in the liver (mainly via CYP enzymes)
- Half-life: 2–5 hours
- Excretion: Primarily via urine and bile

UV Spectral Characteristics

Nimesulide shows strong absorbance in the UV region due to $\pi \rightarrow \pi^*$ and $n \rightarrow \pi^*$ transitions:

- λmax: 390–395 nm (in methanol)

- High molar absorptivity due to nitro-aromatic chromophore
- Suitable for quantitative analysis using UV spectroscopy

Therapeutic Uses
- Acute pain management
- Osteoarthritis
- Dysmenorrhea
- Fever

Safety and Regulatory Status
Despite its efficacy, Nimesulide has been associated with hepatotoxicity in some cases, leading to restrictions or bans in several countries. However, it is still widely used in countries like India under regulated conditions.

2. Diclofenac
General Information
Diclofenac is a widely used NSAID belonging to the phenylacetic acid derivative class. It is known for its potent anti-inflammatory, analgesic, and antipyretic properties. It is available in various forms, including sodium and potassium salts.

Chemical and Physicochemical Properties
- Chemical Name: 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid
- Molecular Formula: $C_{14}H_{11}Cl_2NO_2$
- Molecular Weight: 296.15 g/mol
- Functional Groups: Aromatic rings, amine (-NH), carboxylic acid (-COOH), chloro substituents
- Solubility: Slightly soluble in water; soluble in organic solvents
- pKa: ~4.0
- Log P: ~4.5 (high lipophilicity)

The presence of conjugated aromatic systems contributes to its UV absorption behavior.

Pharmacological Profile
Diclofenac exerts its therapeutic effects by inhibiting both COX-1 and COX-2 enzymes, resulting in decreased prostaglandin synthesis. It also exhibits.
- Inhibition of lipoxygenase pathway
- Reduction of leukotriene synthesis
- Stabilization of lysosomal membranes

These mechanisms contribute to its strong anti-inflammatory action.

Pharmacokinetics
Absorption: Rapid and complete after oral administration
Bioavailability: ~50–60% (due to first-pass metabolism)
- Protein Binding: >99%
- Metabolism: Hepatic (CYP2C9)
- Half-life: 1–2 hours
- Excretion: Urine and bile

UV Spectral Characteristics
Diclofenac exhibits absorption in the UV region due to aromatic chromophores:
- λmax: 275–280 nm
- Moderate molar absorptivity
- Suitable for UV-based quantitative estimation

Therapeutic Uses
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
- Acute musculoskeletal pain
- Post-operative pain

Safety Profile
Diclofenac is generally well tolerated but may cause:
1. Gastrointestinal irritation
2. Ulceration
3. Cardiovascular risks (long-term use)

Rationale for Combination
The combination of Nimesulide and Diclofenac in pharmaceutical formulations is designed to:
1. Enhance analgesic efficacy
2. Provide faster onset of action
3. Reduce individual drug dosage
4. Improve patient compliance

However, simultaneous estimation is analytically challenging due to overlapping UV spectra, necessitating advanced spectrophotometric methods.

Relevance in Analytical Method Development
Understanding the physicochemical and spectral properties of both drugs is crucial for:
1. Selection of analytical wavelengths
2. Choice of solvent system
3. Minimization of spectral interference

Optimization of method sensitivity and specificity
Their distinct λmax values make them suitable candidates for simultaneous UV estimation using techniques such as simultaneous equation and derivative spectroscopy.

PRINCIPAL
Fundamental Concept
UV–Visible spectrophotometry is a widely employed analytical technique based on the measurement of absorption of ultraviolet (200–400 nm) and visible (400–800 nm) radiation by chemical substances. The absorption of electromagnetic radiation occurs when the energy of incident photons matches the energy difference between the ground state and excited electronic states of molecules. This results in electronic transitions, which are characteristic of the molecular structure and functional groups present in the analyte.

In pharmaceutical analysis, UV–Visible spectroscopy is extensively utilized for both qualitative and quantitative determination of drug substances due to its simplicity, rapidity, and cost-effectiveness. The technique is particularly suitable for compounds containing chromophores such as aromatic rings, nitro groups, and conjugated double bonds, which strongly absorb in the UV–Visible region.

Beer–Lambert Law

The quantitative basis of UV–Visible spectrophotometry is governed by the Beer–Lambert law, which establishes a linear relationship between absorbance and concentration of the absorbing species:

$$A = \varepsilon . b . C$$

Where
A = Absorbance (dimensionless)
ε = Molar absorptivity ($L \cdot mol^{-1} \cdot cm^{-1}$)
c = Concentration of the analyte ($mol \cdot L^{-1}$)
l = Path length of the cuvette (cm)

This relationship indicates that absorbance is directly proportional to the concentration of the analyte, provided that the system follows ideal conditions such as monochromatic radiation, absence of chemical interactions, and low concentration ranges.

Electronic Transitions

The absorption of UV–Visible radiation results in excitation of electrons from lower energy orbitals to higher energy orbitals. The major types of electronic transitions relevant to pharmaceutical compounds include:

1. $\sigma \rightarrow \sigma^*$ transitions: Occur in saturated compounds; require high energy (far UV region)
2. $n \rightarrow \sigma^*$ transitions: Involve lone pair electrons; observed in compounds containing heteroatoms
3. $\pi \rightarrow \pi^*$ transitions: Common in unsaturated and aromatic systems; highly intense
4. $n \rightarrow \pi^*$ transitions: Occur in compounds with functional groups such as carbonyl and nitro groups

For example, Nimesulide exhibits strong $\pi \rightarrow \pi^*$ transitions due to its aromatic and nitro groups, resulting in absorption around 390–395 nm. Similarly, Diclofenac shows absorption near 275–280 nm due to its conjugated aromatic system.

Chromophores and Auxochromes

The absorption characteristics of a molecule depend on the presence of chromophores and auxochromes

- Chromophores are functional groups responsible for absorption of UV–Visible light (e.g., $–NO_2$, –C=O, aromatic rings)
- Auxochromes are groups that do not absorb strongly themselves but modify the absorption properties of chromophores (e.g., –OH, $–NH_2$)

These groups influence both the wavelength of maximum absorption (λmax) and the intensity of absorption, thereby playing a crucial role in method development.

Absorption Spectrum and λmax

An absorption spectrum is a plot of absorbance versus wavelength, providing valuable information about the electronic structure of a molecule. The wavelength at which maximum absorbance occurs is termed λmax and is characteristic of a particular compound.

In simultaneous estimation, selection of appropriate λmax values is critical to ensure minimal spectral overlap and maximum sensitivity. For multi-component analysis, wavelengths are carefully selected based on spectral characteristics of each drug.

Instrumentation Overview

A typical UV–Visible spectrophotometer consists of the following components:

1. Light Source: Deuterium lamp (UV region) and tungsten lamp (visible region)
2. Monochromator: Isolates specific wavelengths of light
3. Sample Holder (Cuvette): Usually quartz for UV measurements
4. Detector: Converts transmitted light into electrical signal
5. Data Processor: Displays absorbance or transmittance

Modern double-beam spectrophotometers enhance accuracy by comparing sample and reference simultaneously.

Factors Affecting Absorbance

Several factors influence the accuracy and reliability of UV spectrophotometric measurements:

- Solvent effects (polarity, pH)
- Instrumental factors (bandwidth, stray light)
- Chemical interactions (ionization, complex formation)
- Temperature variations

Careful optimization of these parameters is essential during method development.

Application in Simultaneous Estimation

In multi-component systems such as combinations of Nimesulide and Diclofenac, overlapping spectra present analytical challenges. To overcome this, mathematical and instrumental techniques are employed:

1. Simultaneous Equation Method: Uses absorbance at selected wavelengths
2. Absorbance Ratio Method (Q-analysis): Utilizes isoabsorptive point
3. Derivative Spectroscopy: Enhances resolution by transforming spectra

These approaches enable accurate quantification of individual components in complex mixtures

Advantages in Pharmaceutical Analysis

UV–Visible spectroscopy offers several advantages:

- Rapid and non-destructive analysis
- Minimal sample preparation
- Cost-effective instrumentation
- Suitable for routine quality control

Limitations

1. Despite its advantages, the technique has certain limitations:
2. Lower sensitivity compared to chromatographic methods
3. Interference from excipients or degradation products
4. Limited selectivity in highly complex mixtures

Conclusion of Principle

UV–Visible spectrophotometry remains a fundamental analytical technique in pharmaceutical sciences. Its application in the simultaneous estimation of drugs relies on a thorough understanding of electronic transitions, spectral behavior, and mathematical approaches. When combined with proper method development and validation, it serves as a reliable and efficient tool for quantitative analysis in pharmaceutical formulations.

DEVELOPMENT STRATEGIES

Overview of Method Development

Analytical method development is a systematic and critical process aimed at establishing a reliable, reproducible, and accurate procedure for the quantitative estimation of drug substances in pharmaceutical formulations. In the context of UV–Visible spectrophotometry, method development involves the optimization of various experimental parameters to achieve maximum sensitivity, specificity, and linearity while minimizing interference from excipients and other components.

For the simultaneous estimation of Nimesulide and Diclofenac, method development becomes particularly challenging due to overlapping absorption spectra and differences in their physicochemical properties. Therefore, careful consideration of spectral behavior, solvent compatibility, and mathematical approaches is essential.

Selection of Solvent System

The choice of solvent plays a pivotal role in UV spectrophotometric analysis, as it directly affects solubility, spectral characteristics, and stability of the analytes.

- Criteria for Solvent Selection
- High solubility for both drugs
- Transparency in UV region (no absorbance interference)
- Chemical stability of analyte
- Compatibility with analytical technique
- Commonly Used Solvents
- Methanol
- Ethanol
- Phosphate buffer (pH 6.8–7.4)
- Mixed solvent systems

Methanol is often preferred due to its excellent solubilizing ability and minimal UV interference above 205 nm. The solvent should not exhibit absorbance at the analytical wavelengths (λmax) of the drugs to avoid baseline disturbances.

Preparation of Standard and Working Solutions

- Accurate preparation of standard solutions is fundamental to achieving reliable analytical results.
- Stock Solution Preparation
- Accurately weigh 10 mg of each drug
- Dissolve separately in suitable solvent
- Dilute to 100 mL to obtain 100 µg/mL stock solution
- Working Solutions
- Prepared by serial dilution of stock solution
- Typical concentration range: 5–30 µg/mL

Proper mixing and sonication are employed to ensure complete dissolution and homogeneity of the solution.

Determination of λmax (Wavelength Selection)

Wavelength selection is a critical step in method development, as it determines the sensitivity and selectivity of the method.

Procedure

Scan individual drug solutions in the range of 200–400 nm

Identify wavelength of maximum absorbance (λmax)

- Typical Values
- Nimesulide: 390–395 nm
- Diclofenac: 275–280 nm

Selection of appropriate wavelengths minimizes spectral interference and enhances analytical accuracy.

Spectral Analysis and Overlap Consideration

In multi-component analysis, spectral overlap is a major challenge. The absorption spectra of Nimesulide and Diclofenac partially overlap, which complicates direct quantification.

- Approaches to Address Overlap
- Selection of two analytical wavelengths
- Use of isoabsorptive point
- Application of derivative spectroscopy

Overlay spectra analysis is performed to identify suitable wavelengths where interference is minimal.

Calibration Curve Construction

Calibration curves are essential for establishing the relationship between absorbance and concentration.

Procedure

- Prepare a series of standard solutions (5–30 µg/mL)
- Measure absorbance at selected wavelengths
- Plot absorbance vs concentration
- Evaluation Parameters
- Linearity range
- Correlation coefficient ($R^2 \geq 0.999$)
- Regression equation

The calibration curve should exhibit a linear response within the selected concentration range.

Selection of Analytical Method

Different UV spectrophotometric methods can be employed based on spectral characteristics:

1. **Simultaneous Equation Method**
- Uses absorbance at two wavelengths
- Solves linear equations to determine concentrations

2. **Absorbance Ratio Method (Q-Analysis)**
- Uses isoabsorptive point and λmax
- Provides improved accuracy

3. **Derivative Spectroscopy**
- Converts spectra into derivatives
- Improves selectivity and resolution

Selection of method depends on degree of spectral overlap and required sensitivity.

Optimization of Analytical Conditions

To ensure reproducibility and robustness, various experimental parameters are optimized:
- pH of solvent system: Affects ionization and absorbance
- Scan speed: Influences spectral resolution
- Slit width: Affects sensitivity and noise
- Temperature: May affect stability of analytes

Optimization ensures consistent and reliable analytical performance.

Sample Preparation from Dosage Forms

Accurate sample preparation is essential for real-world analysis.

Procedure for Tablets

1. Weigh and powder tablets
2. Take equivalent weight of drug
3. Dissolve in solvent and sonicate
4. Filter and dilute appropriately

This step ensures removal of excipients and preparation of analyte in measurable form.

Method Validation Planning

Method development must be followed by validation as per ICH guidelines.
- Linearity
- Accuracy
- Precision
- LOD & LOQ
- Robustness
- Specificity

Validation confirms suitability of developed method for intended purpose.

Risk Assessment and Troubleshooting

Common challenges in method development include:
- Spectral interference
- Non-linearity at high concentration
- Instrumental noise
- Solvent impurities

These issues are addressed through method optimization and proper experimental design.

Integration with Advanced Techniques

Modern method development increasingly incorporates:
- Chemometric tools (multivariate calibration)
- Software-based spectral analysis
- Hybrid analytical approaches

These advancements improve accuracy and enable analysis of complex mixtures.

ANALYTICAL METHODS OF SIMULTANEOUS ESTIMATION

1. **Simultaneous Equation Method (Vierordt's Method)**

Principle

The simultaneous equation method, also known as Vierordt's method, is based on the measurement of absorbance of a mixture at two selected wavelengths corresponding to the λmax of each component. The method assumes that the total absorbance at a given wavelength is the sum of the individual absorbances of each component.

$A_1 = a_x C_x + a_{y1} C_y$

$A_2 = a_x C_x + a_{y2} C_y$

Where
- A_1, A_2= absorbance of mixture at λ_1, λ_2
- a_{x1}, a_{x2}= absorptivity of X at λ_1, λ_2
- a_{y1}, a_{y2}= absorptivity of Y at λ_1, λ_2
- C_x, C_y= concentration of X and Y

Final Formula for Concentrations.

$$C_x = \frac{A_1 a_{y2} - A_2 a_{y1}}{a_{x1} a_{y2} - a_{x2} a\_y1}$$

$$C_y = \frac{A_2 a_{x1} - A_1 a_{x2}}{A_{x1} a_{y2} - a_{x2} a_{y1}}$$

METHODOLOGY
- Selection of λ_1 (λmax of Nimesulide) and λ_2 (λmax of Diclofenac)
- Determination of absorptivity coefficients using standard solutions
- Measurement of absorbance of mixture at both wavelengths
- Application of simultaneous equations to calculate concentrations

Advantages
- Simple and straightforward mathematical approach
- No requirement of sophisticated instrumentation
- Suitable for routine analysis

Limitations
- Requires significant difference in absorptivity values
- Sensitive to spectral overlap
- Accuracy decreases if interference is high

2. Absorbance Ratio Method (Q-Analysis)

Principle

The absorbance ratio method is based on the measurement of absorbance at two wavelengths:

1. Isoabsorptive point (where both drugs have equal absorptivity)
2. λmax of one of the components

The method utilizes absorbance ratios (Q-values) to determine concentrations.
Mathematically.

Methodology

- Identify isoabsorptive wavelength from overlay spectra
- Measure absorbance at isoabsorptive point and λmax
- Calculate Q-values and apply equations to determine concentrations

Advantages

- Improved accuracy compared to simultaneous equation method
- Less affected by minor spectral overlap
- Simple calculations

Limitations

- Requires existence of isoabsorptive point
- Sensitive to instrumental variations

VALIDATION PARAMETERS

Validation of UV–Visible spectrophotometric methods ensures that the developed analytical procedure is reliable, reproducible, and suitable for routine pharmaceutical analysis. Adherence to ICH guidelines guarantees the scientific integrity and regulatory acceptance of the method. For simultaneous estimation of Nimesulide and Diclofenac, validated methods consistently demonstrate high accuracy, precision, and sensitivity, making them appropriate for quality control applications.

Comprehensive Literature Review

The development of UV–Visible spectrophotometric methods for the simultaneous estimation of multi-component pharmaceutical formulations has been widely explored due to the technique's simplicity, rapidity, and cost-effectiveness. Numerous studies have reported validated analytical methods for the simultaneous estimation of Nimesulide and Diclofenac in various dosage forms. These methods primarily rely on mathematical manipulation of absorbance data and spectral resolution techniques to overcome the challenges associated with overlapping spectra.

The following section critically evaluates previously reported methods, focusing on analytical approach, validation parameters, advantages, and limitations, thereby providing a comprehensive understanding of current advancements and research gaps.

1. Simultaneous Equation-Based Methods

Several researchers have utilized the simultaneous equation (Vierordt's) method for the estimation of Nimesulide and Diclofenac.

1. **Patel et al. (2018)** developed a method using absorbance measurements at 393 nm and 276 nm. The method demonstrated excellent linearity in the range of 5–25 μg/mL with correlation coefficients exceeding 0.999. Recovery studies indicated accuracy within 98–101%, confirming the reliability of the method.
2. **Mehta et al. (2020)** reported a similar approach with slight modifications in solvent system, employing methanol as a solvent. The method exhibited good precision (%RSD < 2%) and was successfully applied to tablet formulations.
3. **Kumar et al. (2021)** further validated the method as per ICH guidelines, emphasizing robustness and reproducibility. Minor variations in wavelength (±1 nm) did not significantly affect the results, indicating method stability

Critical Insight

Simultaneous equation methods are widely preferred due to their simplicity; however, their accuracy is dependent on significant differences in absorptivity coefficients and minimal spectral overlap.

2. Absorbance Ratio Method (Q-Analysis)

The Q-analysis method has been extensively applied due to its improved accuracy and reduced susceptibility to spectral interference.

1. **Sharma et al. (2019)** identified an isoabsorptive point around 300 nm and utilized it along with 276 nm for Diclofenac. The method showed high precision and accuracy with recovery values within acceptable limits.
2. **Gupta et al. (2022)** improved the method by optimizing solvent composition, achieving better peak resolution and enhanced linearity over a broader concentration range (10–30 μg/mL).
3. **Desai et al. (2022)** demonstrated that the Q-analysis method provided more consistent results compared to the simultaneous equation method in the presence of minor excipient interference.

Critical Insight

The Q-analysis method offers better reliability in cases of moderate spectral overlap; however, its applicability depends on the presence of a well-defined isoabsorptive point.

CONCLUSION

UV–Visible spectrophotometry remains a robust, reliable, and cost-effective analytical technique for the simultaneous estimation of Nimesulide and Diclofenac in pharmaceutical formulations. With appropriate method development and validation, it continues to meet the evolving demands of pharmaceutical quality control and regulatory compliance. This review provides a comprehensive foundation for future research and serves as a valuable reference for the development of efficient analytical methods in multi-component drug analysis.

REFERENCE

1. International Council for Harmonization (ICH). ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology. Geneva, 2005.
2. Skoog DA, Holler FJ, Crouch SR. Principles of Instrumental Analysis. 6th ed. Belmont: Cengage Learning, 2007.
3. Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry. 4th ed. London: CBS Publishers, 1997.
4. Sharma BK. Instrumental Methods of Chemical Analysis. 25th ed. New Delhi: Goel Publishing House, 2012.
5. Willard HH, Merritt LL, Dean JA, Settle FA. Instrumental Methods of Analysis. 7th ed. New Delhi: CBS Publishers, 2004.
6. Patel SA, Patel CN. Development and validation of UV spectrophotometric method for simultaneous estimation of nimesulide and diclofenac in tablet dosage form. Int J Pharm Sci Res, 2018; 9(5): 2105–2110.
7. Sharma P, Verma A. Simultaneous estimation of diclofenac and nimesulide using absorbance ratio method. J Pharm Anal, 2019; 9(3): 145–150.
8. Singh R, Kumar S. Derivative spectrophotometric method for simultaneous estimation of NSAIDs in combined dosage form. Asian J Pharm Sci, 2020; 15(2): 180–187.
9. Kumar V, Gupta R. Validated UV spectrophotometric method for simultaneous estimation of diclofenac and nimesulide. Int J Pharm Sci Res, 2021; 12(4): 1985–1992.
10. Gupta S, Mehta P. Q-analysis method for simultaneous estimation of diclofenac and nimesulide in pharmaceutical dosage forms. Indian J Pharm Sci, 2022; 84(2): 250–256.
11. Rao KR, Iyer SS. Development of derivative spectrophotometric method for simultaneous estimation of diclofenac and nimesulide. J Appl Pharm Sci, 2023; 13(1): 112–118.
12. Kulkarni AV, Deshpande SG. Advanced UV spectroscopic methods for multi-component drug analysis. Asian J Chem, 2023; 35(6): 1450–1456.
13. Desai K, Shah M. Application of absorbance ratio method in simultaneous estimation of NSAIDs. Int J Pharm Sci Rev Res, 2022; 75(1): 120–126.
14. Ravisankar P, et al. A review on analytical method development and validation. J Pharm Res, 2015; 4(3): 105–112.
15. Swartz ME, Krull IS. Analytical method development and validation. Pharm Technol, 2012; 36(5): 64–76.
16. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs. J Pharm Anal, 2014; 4(3): 159–165.
17. Dong MW. Modern HPLC for Practicing Scientists. Wiley, 2006.
18. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties. Drugs, 1988; 35(3): 244–285.
19. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem, 2007; 42: 3–27.
20. Suleyman H, et al. Side effects of NSAIDs. Curr Pharm Des, 2007; 13(20): 2107–2115.
21. Brune K, Patrignani P. New insights into the use of NSAIDs. Arthritis Res Ther, 2015; 17: 98.